EMA · European Union
semuloparin sodium — EMA regulatory status
semuloparin sodium (MULSEVO) regulatory status in the European Union is tracked from public EMA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: EMA application withdrawn.
Status snapshot
- Status
- EMA application withdrawn
- Brand
- MULSEVO
- Mechanism
- Antithrombin-III inhibitor
- Target
- Antithrombin-III
- Structured fields
- 6
Pharmacology context used for competitive intelligence: Antithrombin-III inhibitor. Target: Antithrombin-III. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — EMA: application withdrawn.
Linked evidence on this spoke: 1 published clinical program and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| EMA | European Union | application withdrawn | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| Semuloparin sodium | Phase 3 | Sanofi Pasteur MSD | NCT00714597 |
Related hubs
FAQ
What is the EMA approval status of semuloparin sodium?
semuloparin sodium currently shows EMA application withdrawn in our European Union regulatory index. Confirm on the official EMA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get semuloparin sodium regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to semuloparin sodium?
This spoke lists 1 published program associated with semuloparin sodium in our pipeline index.